Objective-Our aim was to analyze the regulation of CC Chemokine ligand 20 (CCL20) by LDL in human vascular smooth muscle cells (VSMC). Methods and Results-In asymptomatic subjects, circulating CCL20 levels were higher in patients with hypercholesterolemia (18.5Ϯ3.2 versus 9.1Ϯ1.3 pg/mL; PϽ0.01). LDL induced the expression of CCL20 in VSMC in a dose-and time-dependent manner. Increased levels of CCL20 secreted by LDL-treated VSMC significantly induced human lymphocyte migration, an effect reduced by CCL20 silencing. The upregulation of CCL20 by LDL was dependent on the activation of kinase signaling pathways and NF-B. By site-directed mutagenesis, electrophoretic mobility shift assay, and chromatin immunoprecipitation, we identified a NF-B site (Ϫ80/Ϫ71) in CCL20 promoter critical for LDL responsiveness. Lysophosphatidic acid mimicked the upregulation of CCL20 induced by LDL, and minimal oxidation of LDL increased the ability of LDL to induce CCL20 through a mechanism that involves lysophosphatidic acid receptors. CCL20 was overexpressed in atherosclerotic lesions from coronary artery patients, colocalizing with VSMC. CCL20 was detected in conditioned media from healthy human aorta and its levels were significantly higher in secretomes from carotid endarterectomy specimens. Conclusion-This study identifies CCL20 in atherosclerotic lesions and recognizes this chemokine as a mediator highly sensitive to the inflammatory response elicited by LDL. (Arterioscler Thromb Vasc Biol. 2011;31:2733-2741.) 
phages and T lymphocytes are the most abundant inflammatory cells found in atherosclerotic plaques, 9, 10 but also B cells, dendritic cells, and neutrophils contribute to the pathogenesis of atherosclerosis. 9, 11, 12 Native and modified LDL modulate the expression of key genes involved in the recruitment and trafficking of inflammatory cells including cellular adhesion molecules and chemokines such as monocyte chemotactic protein 1. 4, 5, [13] [14] [15] Recent studies have implicated other chemokines in atherosclerosis and have extended the knowledge about the regulation of chemokines/chemokine receptors on vascular cells, 6 -8 but the complete picture of these molecules involved in atherogenesis is not completely understood.
Increasing data involving innate and adaptive immunity in atherosclerosis, 9, 16, 17 and recent reports that emphasize the role of LDL in the response of T cells 18 prompt us to study the regulation of CCL20 (CC Chemokine ligand 20) by LDL. CCL20 is a chemokine that selectively attracts immature dendritic cells, effector/memory T lymphocytes, and naive B cells. 19, 20 As far we know, only one recent study has described the expression of CCL20 by cultured vascular smooth muscle cells (VSMC) from vessels susceptible to atherosclerosis. 21 In the present study, we identify CCL20 as a LDLresponsive gene and dissect the molecular mechanisms underlying the regulation by LDL of this chemokine that is increased in the plasma of hypercholesteromic patients and is upregulated in atherosclerotic lesions from coronary artery patients.
Methods
Detailed explanation of the different experimental procedures is available online at http://atvb.ahajournals.org.
Subjects Characteristics and Assessment of Cardiovascular Risk
A total of 107 apparently healthy subjects, free from clinically manifest atherosclerotic vascular disease, were recruited in the Internal Medicine Department at the University Clinic of Navarra. All subjects underwent ultrasonography of common carotid arteries to assess the carotid intima-media thickness as a direct measure of subclinical atherosclerosis. 22 The institutional ethics committee approved this study, and written informed consent was obtained from all patients. The research was performed in accordance with the Declaration of Helsinki.
Human Artery Sampling and Preservation
Human coronary artery samples were collected from patients undergoing heart transplant surgery at the Hospital de la Santa Creu i Sant Pau (HSCSP) in Barcelona, Spain with the approval of the ethics committee of the HSCSP. Carotid samples were obtained from patients undergoing endarterectomy at the Fundación Jimenez Díaz (FJD) with the approval of the ethics committee of the FJD. Aorta samples (kindly provided by Dr Michel and Dr Meilhac) were obtained from organ donors with the authorization of the French Biomedicine Agency and the approval of the institutional ethics committee CPP Paris Ile de France IV. To obtain secretome, tissues were incubated in serum-free RPMI medium for 24 hours at 37°C. Informed consent was obtained from patients and all studies were in accordance with the Declaration of Helsinki.
Statistical Analyses
Data were expressed as meanϮSD (unless otherwise stated). Significant differences between groups were established by Student t test or 1-way ANOVA, according to the number of groups compared, using the GraphPad Instat program (GraphPad Software V2.03). Differences were considered significant at PϽ0.05. Associations between circulating CCL20 levels and atherosclerotic risk factors were examined by Pearson correlation test for continuous variables, and by unpaired Student t test for categorical variables. Multivariate linear regression analysis was performed to evaluate factors related to CCL20 and atherosclerotic risk factors that were selected by previous statistical evidence of a univariate association.
Results

Circulating CCL20 Levels in Hypercholesterolemic Subjects
After exclusion criteria, 107 subjects free from clinical cardiovascular disease, 54 normocholesterolemic (total cholesterol Յ239 mg/dL), and 53 hypercholesterolemic (total cholesterol Ն240 mg/dL) were included (Table) . No significant differences in the prevalence of cardiovascular risk factors other than hypercholesterolemia were observed between both groups. Circulating levels of CCL20 were significantly higher in subjects with hypercholesterolemia ( Figure 1 ). Hypercholesterolemic subjects also exhibited a higher cardiovascular risk as determined by the PROCAM (Prospective Cardiovascular Münster) score and higher circulating levels of inflammatory markers including fibrinogen, hs-CRP, and IL-6. CCL20 levels were positively correlated with total cholesterol (rϭ0.20, PϽ0.05), LDL-cholesterol (rϭ0.20, PϽ0.05), and IL-6 (rϭ0.28, PϽ0.01). The association between CCL20 and hypercholesterolemia remained significant in multiple regression analysis after adjustment for other atherosclerotic risk factors (Betaϭ0.26, Pϭ0.006).
LDL Induce CCL20 Expression in Human VSMC
CCL20 expression was upregulated by LDL in a time-dependent manner, reaching a maximum after 4 hours (Supplemental Figure IA) . The effect was dose-dependent, was significant at 50 g/mL, and maximal at 300 g/mL (Supplemental Figure IB) . We choose 4 hours of treatment and 300 g/mL LDL for further experiments. LDL also induced CCL20 expression in endothelial cells from human umbilical veins with a similar temporal pattern to that observed in VSMC (Supplemental Figure IC) .
LDL Induce CCL20 Secretion in Human VSMC
Levels of CCL20 secreted by human VSMC treated with LDL were significantly higher than those detected in control cells (Figure 2A ). In cell migration assays, supernatants from LDLtreated VSMC promoted human lymphocytes migration in a similar extent than human recombinant CCL20 at a concentration equivalent to that found in these media (40 pg/mL) ( Figure  2B and 2C). Cell supernatants from VSMC treated with siRNA that efficiently prevented the upregulation of CCL20 expression and the secretion of CCL20 induced by LDL ( Figure 2D , left and middle panels) significantly reduced lymphocyte migration ( Figure 2D , right panel).
LDL Increase CCL20 Transcriptional Activity in VSMC Through a NF-B Response Element
Pretreatment of human VSMC with a transcriptional inhibitor prevented the increase in CCL20 mRNA levels elicited by LDL ( Figure 3A ). Accordingly, in transient transfection assays LDL increased CCL20 promoter activity ( Figure 3B ). Analysis of the CCL20 promoter sequence revealed several conserved putative binding sites for transcription factors potentially regulated by LDL among them a cAMP response element, an AP-1 and a NF-B. Parthenolide and BAY 11-7082 (2 NF-B inhibitors) but not NDGA (an AP-1 inhibitor) significantly prevented the upregulation of CCL20 by LDL ( Figure 3C ). LDL significantly activate NF-B signaling in human VSMC, promoting a decrease in cytosolic levels of IB␣ that parallels the translocation of p65 from the cytosol to the nucleus, effect that was prevented by parthenolide ( Figure 3D and 3E).
We analyzed a series of promoter deletions and delimited LDL responsiveness to a proximal promoter region that contains a putative NF-B site (Ϫ80/Ϫ71). Mutation of this response element abrogated LDL-induced CCL20 promoter activity ( Figure 4A and 4B). Consistent with this, EMSA analysis showed that LDL increase the binding to this NF-B site ( Figure 4C , left panel). The CCL20 probe formed several complexes with nuclear proteins from human VSMC. These DNA-binding complexes disappeared in competition experiments, and addition of an antibody against p65 supershifted complexes I and II ( Figure 4C , middle and right panel). Finally, chromatin immunoprecipitation assays confirmed that, in vivo, NFB binds to this site, and that LDL significantly increased NFB binding ( Figure 4D ).
Signaling Pathways Involved in CCL20 Induction by LDL
We used specific inhibitors in order to identify the pathways involved in the upregulation of CCL20 by LDL. LDLinduced CCL20 expression was dependent on calcium mobilization (inhibited by BAPTA-AM), PKC (inhibited by GF10933X), ERK1/2 (inhibited by U0126), and p38 MAPK activation (inhibited by SB203580) (Supplemental Figure  IIA) . The activation of ERK1/2 and p38 MAPK by LDL in VSMC as well as the inhibition exerted by U0126 and SB203580 is shown in Supplemental Figure IIB 
Upregulation of CCL20 by LDL Is Mediated by Lysophosphatidic Acid Receptors
Blocking antibodies against different lipoprotein receptors including the LDL receptor, scavenger receptor class A type I, lectin-like oxidized LDL receptor 1, and CD36 did not significantly modified the upregulation of CCL20 induced by LDL (Supplemental Figure III) . By contrast, pertussis toxin, an inhibitor of receptors coupled to G i/o -proteins, significantly reduced CCL20 mRNA levels induced by LDL (data not shown) suggesting the involvement of a bioactive component carried by LDL. Products of LDL oxidation Figure 1 . Circulating CCL20 levels in normo-and hypercholesterolemic subjects. Circulating CCL20 levels in normocholesterolemic (total cholesterol Յ239 mg/dL; nϭ54) and hypercholesterolemic subjects (total cholesterol Ն240 mg/dL; nϭ53). Data are expressed as meanϮSEM (PϽ0.01: *vs normocholesterolemic subjects).
(7-ketocholesterol, 25-hydroxycholesterol, and 4-HNE), even at concentrations that largely exceed those that could be found in native LDL, 23 did not affect CCL20 expression (Supplemental Figure IV) . By contrast, low concentrations of lysophosphatidic acid (LPA) induced CCL20 expression mimicking the effect of LDL. Minimally oxidation of LDL, a modification that increase LPA content, 24, 25 potentiated the ability of LDL (100 g/mL) to induce CCL20 expression (Supplemental Figure V) . Interestingly, Ki-16425 (an antagonist of LPA receptors) impaired MAPK pathways involved in CCL20 modulation by LDL and reduced both CCL20 mRNA levels and CCL20 transcriptional activity induced by LDL and moxLDL (Supplemental Figure V ).
CCL20 Is Induced in Human Atherosclerotic Coronary Arteries
The expression of CCL20 in human coronary arteries from patients with coronary artery disease (CAD) was analyzed and compared with vessels from patients without atherosclerosis. The mRNA of this chemokine was weakly expressed in nonatherosclerotic arteries but significantly upregulated in atherosclerotic lesions (Ϸ20-fold induction, PϽ0.05) ( Figure   5A ). Upregulation of CCL20 expression was as high as that of monocyte chemotactic protein 1, a well-known chemokine involved in inflammation/atherogenesis; moreover, we observed a significant increase in mRNA levels of its receptor (CCR6). EMSA using a probe containing the NF-B response element present in CCL20 promoter, showed higher DNAbinding activity in atherosclerotic arteries compared with nonatherosclerotic ones (Figure 5B) , and by immunohistochemistry, CCL20 was mainly colocalized with VSMC in the intima of atherosclerotic coronary arteries ( Figure 5C ).
CCL20 Is Released By Vascular Tissues
To assess whether vascular cells could be a source of CCL20, we analyzed CCL20 levels in secretomes from intima-media layers of human vessels. CCL20 was detected in conditioned media from healthy human aorta and its levels were significantly higher in secretomes from human carotid endarterectomy specimens ( Figure 5D ).
Discussion
The onset and progression of atherosclerosis parallels the influx of inflammatory cells into the vessel wall. 6,9 LDL play a key role in this "call-effect" as these lipoproteins modulate the expression of vascular cell adhesion molecules, chemokines, and chemokine receptors involved in the recruitment and trafficking of inflammatory cells. 4, 5 Despite the welldocumented presence of active T cells, 16 and dendritic cells 11 in human plaques, chemokines involved in the recruitment of inflammatory cells other than monocytes/macrophages remain incompletely understood. Moreover, there is no information concerning CCL20 regulation in VSMC and atherosclerosis. In the present study, we found increased CCL20 levels in serum from hypercholesterolemic patients; moreover, CCL20 was significantly upregulated in atherosclerotic lesions. In cultured human vascular cells, LDL induced biologically relevant levels of this chemokine through a transcriptional mechanism mediated by NF-B.
CCL20 was identified in 1997 by 3 independent groups in screens of human cDNA libraries from liver, monocytes, and pancreatic cells and was called liver and activated-regulated chemokine, macrophage inflammatory protein-3␣, and Exodus, respectively. 19 CCL20 is a constitutive/homeostatic and inducible/inflammatory chemokine. Indeed, CCL20 is expressed both constitutively and inducibly in response to proinflammatory stimuli in lymphoid and nonlymphoid tissues and cells. 19, 20 CCL20 is the unique chemokine ligand for CCR6, a receptor with a restricted distribution in tissues and cells such as immature dendritic cells, effector/memory T lymphocytes, and naive B cells. 19, 20, 26 CCL20 is typically expressed at low basal levels but can be strongly induced by diverse proinflammatory stimuli. 19, 26 In fact, CCL20 is upregulated in inflamed areas, in particular in epithelial surfaces, in pathologies such as arthritis or cancer. 19, 27 Here, we show that circulating levels of CCL20 were significantly higher in subjects with hypercholesterolemia, and besides total cholesterol or LDL-cholesterol, they were positively correlated with serum levels of IL-6, an inflammatory mediator regulated by LDL in vascular cells. 28 This is the first study showing that this chemokine, recently proposed as a potential biomarker in inflammatory diseases including rheumatoid arthritis and certain carcinomas, 29, 30 could be a new inflammatory marker associated to hypercholesterolemia.
LDL upregulated CCL20 expression in human VSMC and increased the release of CCL20 to levels that significantly induced human lymphocyte migration in a transwell assay, supporting the biological significance of these findings. This effect involved Ca 2ϩ mobilization, the activation of PKC and MAPK (ERK1/2 and p38 MAPK), interrelated pathways commonly activated by LDL in vascular cells, 14, 31, 32 that have been associated to the CCL20 induction by other stimuli in diverse cell types. [33] [34] [35] In transient transfection assays we showed that LDL increased the transcriptional activity of human CCL20 promoter. In silico analysis of CCL20 promoter identified Figure 3 . LDL induce CCL20 expression through a transcriptional mechanism that involves NF-B. A, Vascular smooth muscle cells (VSMC) were induced with 300 g/mL LDL for 4 hours in the presence or in the absence of 5,6-dicloro-1-(b-D-ribofuranosil)benzimidazol (DRB) and CCL20 expression was analyzed (nϭ9; PϽ0.05: *vs control cells; #vs cells treated with LDL alone). B, VSMC were transfected with the pCCL20/-2007 construct and treated with LDL (300 g/mL for 7 hours) (nϭ9; PϽ0.05: *vs control cells). C, Effect of NDGA, parthenolide (Part) and BAY 11-7082 (BAY) on CCL20 mRNA levels induced by LDL (300 g/mL for 4 hours) (nϭ9; PϽ0.05: *vs controls; #vs LDL alone). D, VSMC were treated with LDL (300 g/mL) in the presence or absence of parthenolide, and cytosolic or nuclear extracts were analyzed by Western blot. Representative immunoblots using antibodies against IB␣ and p65 are shown. Beta-actin and nucleolin (Nucl.) were used as a loading control for citosolic and nuclear extracts, respectively. E, Confocal microscopy analysis showing the mobilization of p65 to the nuclei in cells stimulated with LDL and the preventive effect exerted by parthenolide (LDL/Part).
several elements corresponding to transcription factors potentially activated by LDL through the signaling pathways mentioned above, among them CREB, AP-1 and NF-B. 31, 36, 37 Because these transcription factors have been involved in the regulation of inducible chemokines including CCL20, 34, 35 as a first approach we showed that inhibitors of NF-B signaling prevented the upregulation of CCL20 mRNA levels. The involvement of a NF-B site located in the proximal region of CCL20 promoter was demonstrated by serial deletion analysis of promoter-luciferase constructs, site-directed mutagenesis, EMSA, and chromatin immunoprecipitation assays. It is noteworthy that NF-B has also been involved in the modulation of CCL20 by other mediators such as TNF␣ in a human cancer cell line, 38 prolactin in keratinocytes, 35 or hypoxia in primary human monocytes/ macrophages. 39 Taken together these results emphasize the role of NF-B in the modulation of CCL20 by lipoproteins and other inducers. Concerning the mechanism involved in such effect, lipoprotein receptors do not seem to play a major role. By contrast, several data suggest the involvement of a bioactive component of LDL (LPA) and its receptors. Indeed, minimal oxidation of LDL, a process that increases the content of LPA 24,25 without significantly affecting apolipoprotein B, 40, 41 increased the ability of LDL (moxLDL) to upregulate CCL20 expression. Moreover, low LPA concentrations mimicked this lipoprotein effect while other products of LDL oxidation, at concentration that largely exceed those likely to be present in native LDL preparations, 23 did not. Finally, Ki-16425, an antagonist of LPA receptors (mainly LPA1 and LPA3 and in a lesser extent LPA2), was able to prevent the activation of signaling pathways involved in the upregulation of CCL20 by LDL, as well as the increase in CCL20 expression and CCL20 transcriptional activity induced by LDL. Therefore, CCL20 modulation by LDL seems to be associated to the activation of LPA receptors, receptors that have been involved in a number of biological activities of LDL, 24, 25, 42, 43 and that seem to participate in atherosclerosis as suggested a recent study showing that Ki-16425 is able to reduce diet-induced atherosclerosis in apoE-deficient mice. 44 CCL20 and its receptor seem to be critical for the arrest of rolling lymphocytes under flow conditions. 45 However, studies that early identified the expression of several chemokines chemoattractans for lymphocytes in carotid specimens from patients subjected to endarterectomy 46 failed to detect CCL20 by conventional PCR or in situ hybridization. Most recently, however, Yilmaz et al 47 described the presence of CCL20 in carotid plaques associated with inflammatory cells. In the present study, we detected a strong upregulation of CCL20 in human atherosclerotic lesions from CAD patients suggesting an active role of the CCL20/CCR6 system in atherosclerosis. In fact, the upregulation of CCL20 in these atherosclerotic lesions was as higher as that of monocyte chemotactic protein 1, a well-known NF-B-regulated chemokine involved in inflammation/atherogenesis. CCL20 mainly colocalized with VSMC in atherosclerotic coronary arteries and was associated with an enhanced NF-B binding activity in these lesions, in agreement with the key role of this pathway in vascular inflammation. Finally, CCL20 was detected in conditioned media from healthy human vessels and its levels were significantly higher in secretomes from human atherosclerotic lesions, suggesting that vascular cells could be a source of this chemokine. A limitation of our study, however, is the low number of human artery specimens analyzed due to the limited access to these samples. Furthermore, the potential of CCL20 as a biomarker should be validated in largest studies with patients affected by different pathological disorders associated with vascular inflammation.
In summary, in the present study we identify CCL20 in human coronary atherosclerotic lesions and recognize this chemokine as a mediator highly sensitive to the inflammatory response elicited by hypercholesterolemia in vivo and by LDL in vitro. CCL20 could be regarded as a new player in atherogenesis and a NF-B downstream target potentially useful for strategies aimed to improve the balance between pro-and antiinflammatory mediators. Indeed, emerging evidence from experimental studies and clinical trials support the use of inflammation status as a clinical tool to aid prevention and guide the therapy and management of cardiovascular disease. 3 Moreover, handling the chemokine system could open new therapeutic perspectives. 48 The strict selectivity of CCL20 for CCR6, one of the exceptions to the common promiscuity among chemokines and their receptors, makes this tandem attractive for selective interventions addressed to an inflammatory subset of cells involved in atherogenesis. Interestingly, recently Wan et al 49 have shown that genetic deletion of the CCL20 receptor (CCR6) decreases atherogenesis in apoE-deficient mice. Further studies are warranted to better understand the pathophysiological role Figure 5 . Atherosclerotic coronary arteries show increased CCL20 mRNA levels and NF-B activity. A, mRNA levels of CCL20, CCR6, and monocyte chemotactic protein 1 (MCP-1) in human nonatherosclerotic coronary arteries (non-ATC; nϭ7; white bars) and human atherosclerotic coronary arteries (ATC; nϭ7; black bars). Data are expressed as meanϮSEM (PϽ0.05: *vs non-ATC). B, Representative EMSA performed with the CCL20-88/-65 probe and whole-protein extracts from non-ATC (nϭ6) and ATC (nϭ6). Arrowheads indicate the main complexes upregulated in ATC and competed with a molar excess of unlabeled probe (ϫ100). C, High-power views showing immunostaining corresponding to CCL20, ␣-SMA (marker of VSMC), and the merge image (nuclei staining in blue) demonstrating their colocalization in the intima of a representative ATC (nϭ4). CT indicates control immunostaining of a consecutive section incubated with nonimmune goat IgG. Barϭ20 m. D, CCL20 levels in conditioned media from human vascular tissues. Intima-media layers from carotid endarterectomy specimens (atheroma; nϭ15) and healthy aortas (control; nϭ8) were incubated in serum-free medium (24 hours at 37°C), and CCL20 levels were analyzed by EIA. CCL20 levels were normalized by protein concentration. Data are expressed as meanϮSEM (*PϽ0.001 vs aorta controls).
of CCL20/CCR6 in vascular homeostasis and human atherosclerosis.
